BOXED O
WARNING O
: O
WARNING O
: O
LOWER O
LIMB O
AMPUTATION O
WARNING O
: O
LOWER O
LIMB O
AMPUTATION O
* O
An O
approximately O
2-fold O
increased O
risk O
of O
lower B-OSE_Labeled_AE
limb I-OSE_Labeled_AE
amputations I-OSE_Labeled_AE
associated O
with O
INVOKANA O
use O
was O
observed O
in O
CANVAS O
and O
CANVAS-R O
, O
two O
large O
, O
randomized O
, O
placebo-controlled O
trials O
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
who O
had O
established O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
( I-Not_AE_Candidate
CVD I-Not_AE_Candidate
) O
or O
were O
at O
risk O
for O
CVD B-Not_AE_Candidate
. O

* O
Amputations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
toe I-OSE_Labeled_AE
and O
midfoot O
were O
most O
frequent O
; O
however O
, O
amputations B-OSE_Labeled_AE
involving I-OSE_Labeled_AE
the I-OSE_Labeled_AE
leg I-OSE_Labeled_AE
were O
also O
observed O
. O

Some O
patients O
had O
multiple O
amputations B-OSE_Labeled_AE
, O
some O
involving O
both O
limbs O
. O

* O
Before O
initiating O
, O
consider O
factors O
that O
may O
increase O
the O
risk O
of O
amputation B-NonOSE_AE
, O
such O
as O
a O
history O
of O
prior O
amputation B-Not_AE_Candidate
, O
peripheral B-Not_AE_Candidate
vascular I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
neuropathy B-Not_AE_Candidate
, O
and O
diabetic B-Not_AE_Candidate
foot I-Not_AE_Candidate
ulcers I-Not_AE_Candidate
. O

* O
Monitor O
patients O
receiving O
INVOKANA O
for O
infection B-NonOSE_AE
, O
new O
pain B-NonOSE_AE
or O
tenderness B-NonOSE_AE
, O
sores B-NonOSE_AE
or O
ulcers O
involving I-NonOSE_AE
the I-NonOSE_AE
lower I-NonOSE_AE
limbs I-NonOSE_AE
, O
and O
discontinue O
if O
these O
complications O
occur O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
LOWER O
LIMB O
AMPUTATION O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
In O
patients O
with O
type O
2 O
diabetes O
who O
have O
established O
cardiovascular O
disease O
( O
CVD O
) O
or O
at O
risk O
for O
CVD O
, O
INVOKANA O
has O
been O
associated O
with O
lower O
limb O
amputations O
, O
most O
frequently O
of O
the O
toe O
and O
midfoot O
; O
some O
also O
involved O
the O
leg O
( O
5.1 O
) O
* O
Before O
initiating O
, O
consider O
factors O
that O
may O
increase O
the O
risk O
of O
amputation O
. O

Monitor O
patients O
receiving O
INVOKANA O
for O
infections O
or O
ulcers O
of O
the O
lower O
limbs O
, O
and O
discontinue O
if O
these O
occur O
. O

( O
5.1 O
) O

